On this page
Our read
NPPA is likely to face pressure to justify or widen its 30% margin cap beyond cancer drugs.
For operators
Pharmacy operators should model the hit from a 30% of MRP trade margin cap on about 110 medicines, with MRP cuts of up to 70%, and prepare for the cap reaching other medicines and devices, since the Supreme Court has asked why it covers only anti-cancer drugs.
Watch
Supreme Court signal to take the 30% cap past anti-cancer drugs at the 27 October hearing would mean chemists and distributors of other medicines face margin cuts.
The report, : Supreme Court asks why 30% trade margin cap covers only cancer drugs; next hearing 27 October
The Supreme Court on Monday questioned why the 30% trade margin cap applies only to cancer drugs and not other medicines and devices. The cap is expected to cover around 110 medicines, and the next hearing is on October 27.
- Medicines expected to be covered
- around 110
- Of which patented
- 35
- Possible MRP reduction
- up to 70%
- Estimated annual patient savings
- Rs 2,500 crore
One email each morning: the day’s top moves in Indian retail, why each matters and what to watch. Free. Stop any time.
Reported figures
From the report. Source details below
| Patented drugs among those covered: | 35 |
|---|---|
| Possible MRP reduction: | up to 70% |
| Estimated annual patient savings: | Rs 2,500 crore |
| 2019 capped non-scheduled cancer medicines: | 42 |
| 2019 brands with price cuts: | 526 |
| 2019 estimated annual savings: | Rs 984 crore |
What to watch next
- NPPA affidavit explaining the oncology-only scope
- Final list size against the ~110 medicines, including the 35 patented
- Interim stay or relief sought by manufacturers or trade bodies
- Retail chemist and distributor association statements on margin impact
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- NPPA is likely to file a written defence of why the 30% cap targets anti-cancer drugs first, citing price burden and patient savings.
- The Department of Pharmaceuticals may be asked to say whether the cap can extend to other medicines and devices, and on what timeline.
- Drug makers with patented products among the ~35 covered may seek hearings or exemptions, arguing that deep MRP cuts hurt supply.
- Chemist, distributor and hospital pharmacy associations are likely to seek to intervene, fearing the cap becomes a template for wider margin curbs.
- Expect NPPA to hold back any broader margin notification until the Court's direction after 27 October is clear.
The source
Published
First seen